Statins interfere with the attachment of S. cerevisiae mtDNA to the inner mitochondrial membrane.
Angela CiriglianoAntonia AmelinaBeatrice BiferaliAlberto BoffiChiara MozzettaMichele Maria BianchiMattia MoriBruno BottaElah PickRodolfo NegriTeresa RinaldiPublished in: Journal of enzyme inhibition and medicinal chemistry (2019)
The 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme of the mevalonate pathway for the synthesis of cholesterol in mammals (ergosterol in fungi), is inhibited by statins, a class of cholesterol lowering drugs. Indeed, statins are in a wide medical use, yet statins treatment could induce side effects as hepatotoxicity and myopathy in patients. We used Saccharomyces cerevisiae as a model to investigate the effects of statins on mitochondria. We demonstrate that statins are active in S.cerevisiae by lowering the ergosterol content in cells and interfering with the attachment of mitochondrial DNA to the inner mitochondrial membrane. Experiments on murine myoblasts confirmed these results in mammals. We propose that the instability of mitochondrial DNA is an early indirect target of statins.
Keyphrases
- mitochondrial dna
- cardiovascular disease
- copy number
- saccharomyces cerevisiae
- oxidative stress
- healthcare
- end stage renal disease
- induced apoptosis
- ejection fraction
- type diabetes
- chronic kidney disease
- cell death
- prognostic factors
- dna methylation
- gene expression
- cell proliferation
- low density lipoprotein
- late onset
- genome wide
- patient reported outcomes
- combination therapy